Kamil Ali-Jackson

Kamil Ali-Jackson is the founder of NeXeption LLC, founded in 2011.
Ms. Ali-Jackson is the founder of Aclaris Therapeutics, Inc., founded in 2012, and served as Secretary, Chief Legal & Chief Compliance Officer from 2012 to 2022.
Ms. Ali-Jackson was the founder of Nexeption, Inc., founded in 2011, and served as Chief Legal Officer from 2011 to 2020.
Current jobs include Independent Director at Rigel Pharmaceuticals, Inc. since 2021; Independent Director at PDS Biotechnology Corp.
since 2020; Trustee at Rosemont College; Chief Legal Officer at Nexeption II LLC since 2011; Chief Legal Officer at Nst Consulting LLC since 2011; and Trustee at Princeton University.
Former jobs include Director at PDS Operating Corp.; Independent Director at Moda Operandi, Inc.; Legal Counsel at Merck & Co., Inc. from 1990 to 1998; Secretary, Chief Compliance & Legal Officer at Ceptaris Therapeutics, Inc. from 2011 to 2013; Secretary & General Counsel at Ception Therapeutics, Inc. from 2006 to 2010; Vice President & Associate General Counsel at Endo Pharmaceuticals, Inc. from 1998 to 2000; General Counsel at Caresoft, Inc.; Vice President-Legal & Associate General Counsel at Dr. Reddy's Laboratories, Inc. from 2004 to 2006; Interim General Counsel at Iroko Pharmaceuticals LLC from 2011 to 2012; Chief Legal Officer at Network Sensing Technologies LLC; and Chief Legal Officer at Ralexar Therapeutics, Inc. from 2014 to 2015.
Education includes undergraduate degree from Princeton University and graduate degree from Harvard Law School, conferred in 1984.